This week's Houston innovators to know includes Sola Lawal of Nuro, Jose Diaz-Gomez of CHI St. Luke's Health, and Kimberly Baker of UT School of Public Health. Courtesy photos

Editor's note: A key attribute of innovators and inventors is the ability to look forward — to see the need for their innovation and the difference it will make. Each of this week's innovators to know have that skill, whether it's predicting the rise of autonomous vehicles or seeing the future of health care.

Sola Lawal, product operations manager at Nuro

Autonomous vehicle delivery service is driving access to food in Houston’s vulnerable communities

Native Houstonian Sola Lawal is looking into how AI and robotics can help increase access to fresh foods in local food deserts. Photo courtesy of Nuro

Sola Lawal has always found himself back in his hometown of Houston. Now working for artificial intelligence and robotics company, Nuro, he sees the potential Houston has to become a major market for autonomous vehicles.

"I think that autonomous vehicles are going to become an industry in the same way your standard vehicles are," Lawal says."One really strong way the Houston ecosystem and Nuro can partner is essentially building out the ancillary."

Lawal shared more on how Houston and Nuro can work together on this week's episode of the Houston innovators podcast. Read more and stream the episode.

Jose Diaz-Gomez, an anesthesiologist at CHI St. Luke's Health

CHI St. Luke's Health has invested in around 40 of the Butterfly iQ devices that can be used to provide accurate and portable ultrasonography on COVID-19 patients. Photo courtesy of CHI St. Luke's

A new, portable ultrasound device has equipped Jose Diaz-Gomez and his team with a reliable, easy-to-use tool for diagnostics and tracking progress of COVID-19 patients. And this tool will continue to help Diaz-Gomez lead his team of physicians.

"Whatever we will face after the pandemic, many physicians will be able to predict more objectively when a patient is deteriorating from acute respiratory failure," he says. "Without this innovation, we wouldn't have been able to be at higher standards with ultrasonography." Read more.

Kimberly A. Baker, assistant professor at UTHealth School of Public Health

UTHealth School of Public Health launched its Own Every Piece campaign to promote women's health access and education. Photo courtesy of Own Every Piece

It was unnerving to Kimberly Baker that proper sex education wasn't in the curriculum of Texas schools, and women were left without resources for contraceptives. So, along with UTHealth School of Public Health, she launched its Own Every Piece campaign as a way to empower women with information on birth control and ensure access to contraceptive care regardless of age, race, relationship status or socioeconomic status.

"You feel like the campaign is talking to you as a friend, not talking down to you as an authority or in any type of shaming way," says Kimberly A. Baker, assistant professor at UTHealth School of Public Health. One of her favorite areas of the website is the "Find a Clinic" page, connecting teens and adult women to nearby clinics, because "one of the biggest complaints from women is that they didn't know where to go," says Baker. Continue reading.

UTHealth School of Public Health launched its Own Every Piece campaign to promote women's health access and education. Photo courtesy of Own Every Piece

This Houston organization is rethinking access to and education on women's health

women's health

If you browse through the required school curriculum in Texas, you might be surprised to find that sex ed doesn't quite make the cut. Sex education is optional in the Lone Star State and state law requires schools to stress abstinence when choosing to teach the subject, which can make understanding birth control even more confusing for both teens and adult women.

UTHealth School of Public Health launched its Own Every Piece campaign as a way to empower women with information on birth control and ensure access to contraceptive care regardless of age, race, relationship status or socioeconomic status. One click to the Own Every Piece website and you'll be greeted by the smiles of diverse women, along with videos of their birth control journey and educational information on various birth control options.

"You feel like the campaign is talking to you as a friend, not talking down to you as an authority or in any type of shaming way," says Kimberly A. Baker, assistant professor at UTHealth School of Public Health. One of her favorite areas of the website is the "Find a Clinic" page, connecting teens and adult women to nearby clinics, because "one of the biggest complaints from women is that they didn't know where to go," says Baker.

The website and social media platforms preach of body-positivity, empowerment, and knowledge. Prompts from a "true or false"-style quiz debunk myths from birth control weight gain to proper condom use on the home page. In the name of inclusivity, women can even upload their own birth control story to share with Own Every Piece's audience.

Baker and her team got their start in school districts developing programs for middle and high schoolers while also training teachers on how to discuss birth control openly. After working in over 20 school districts with the goal of preventing teen pregnancy through education, Baker identified a new problem: the significant lack of access to health care within the Houston community.

"We wanted to figure out what the major gaps were," Baker says. "What we found, of course, was how expensive birth control was — especially with some of the most effective methods."

Kimberly A. Baker is assistant professor at UTHealth School of Public Health. Photo courtesy of Own Every Piece

Let's crunch some numbers. When interpreting the price of contraceptives, the type of birth control and access to health care can impact how much women pay out-of-pocket. According to Baker, the standard pill can cost anywhere from $10 to $30 a month while implanting long-acting reversible contraceptives like the IUD can cost upwards of $600 to $700. These calculations don't factor in the cost of a doctor's appointment, the removal of a device like the IUD, or even the average $4,500 it costs to give birth if you choose to have a child in the U.S.

After noticing gaps in who could pay for service, Baker and her team realized that some community centers didn't have the funds to have long-acting contraceptive on hand.

"We knew if we partnered with health clinics and health centers to help train them to better serve folks that they weren't serving well, and to give them more funds to buy methods that women couldn't probably afford...we would be filling that gap," she says.

Creating comfort and trust among women looking for contraceptives was another key intention in the campaign's launch.

"When [women] enter a community health clinic, they should feel confident to ask questions and to know that they're receiving all the accurate information they should be getting so they can make the best decision for them," says Baker.

Baker likes to think of the Own Every Piece project as a "more celebratory campaign around birth control that we hadn't seen before," she says. "There are so many stereotypes around sexuality and reproduction that are very shame-based," says Baker, particularly for "Latinx and Black women."

She acknowledges how epithetical birth control messaging that suggests women shouldn't "have more kids" or implies "pregnancy is a bad thing" frames reproductive health in a negative way. "We wanted a campaign that let women know that they own their body. They make decisions about their body, and birth control is a piece of that," she says.

The purpose of providing access took on a new meaning when the coronavirus hit. Since Own Every Piece began as a digital campaign targeted to Houston women ages 18 to 30, the initiative had a head start in the race to move online.

"We saw an opportunity to figure out how we can tell our community health centers to get into the telecontraception space because we've already established trust virtually through our campaign," explains Baker.

Prior to the COVID-19 pandemic, Texas held the title of the state with the most uninsured residents in the U.S. In a state with 2.9 million unemployment claims since March, access to affordable birth control has never been more essential for women.

"From women who lost their insurance due to losing their job because of COVID-19, this has been a godsend," says Baker.

Telemedicine has also added convenience for women who didn't have the time to check out a clinic in-person before the pandemic.

While COVID-19's strains on American health care continue to dominate headlines, birth control has also managed to make national news. On July 8, the Supreme Court ruled that employers can opt-out of birth control coverage—a decision that could result in an estimated 126,000 women losing contraceptive coverage from their employers, according to the New York Times.

The 7-to-2 Supreme Court decision is the latest in a seven-year-long litigation over religious objections to birth control. Outside of pregnancy prevention, birth control helps women cope with premenstrual dysmorphic disorder, polycystic ovarian syndrome, endometriosis, acne, and a number of other issues.

"We have to work harder to have inclusive messaging around [birth control usage], because birth control isn't just about pregnancy prevention," explains Baker. "People use birth control for a number of needs. When you message it just around pregnancy prevention, people start to feel like something is wrong with being pregnant, and that's not what we set out to do."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers: Here's what it takes to spot a great new idea

houston voices

Having a “promotion focus” really does create a mental lens through which new ideas are more visible.

Key findings:

  • New ideas can be crucially important to businesses, driving innovation and preventing stagnation.
  • Recognizing those ideas, though, isn’t always easy.
  • Nurturing what is known as “promotion focus” can help managers spot fresh ideas.

Whenever the late surgeon Michael DeBakey opened a human chest, he drew on a lifetime of resources: the conviction that heart surgery could and should be vastly improved, the skill to venture beyond medicine’s known horizons and the vision to recognize new ideas in everyone around him, no matter how little formal training they had.

Appreciating new ideas is the heartbeat of business as well as medicine. But innovation is surprisingly hard to recognize. In a pioneering 2017 article, Rice Business Professor Jing Zhou and her colleagues published their findings on the first-ever study of the traits and environments that allow leaders to recognize new ideas.

Recent decades have produced a surge of research looking at how and when employees generate fresh ideas. But almost nothing has been written on another crucial part of workplace creativity: a leader’s ability to appreciate new thinking when she sees it.

Novelty, after all, is what drives company differentiation and competitiveness. Work that springs from new concepts sparks more investigation than work based on worn, already established thought. Companies invest millions to recruit and pay star creatives.

Yet not every leader can spot a fresh idea, and not every workplace brings out that kind of discernment. In four separate studies, Zhou and her coauthors examined exactly what it takes to see a glittering new idea wherever it appears. Their work sets the stage for an entirely new field of future research.

First, though, the team had to define their key terms. “Novelty recognition” is the ability to spot a new idea when someone else presents it. “Promotion focus,” previous research has shown, is a comfort level with new experiences that evokes feelings of adventure and excitement. “Prevention focus” is the opposite trait: the tendency to associate new ideas with danger, and respond to them with caution.

But does having “promotion focus” as opposed to “prevention focus” color the ability to see novelty? To find out, Zhou’s team came up with an ingenious test, artificially inducing these two perspectives through a series of exercises. First, they told 92 undergraduate participants that they would be asked to perform a set of unrelated tasks. Then the subjects guided a fictional mouse through two pencil and paper maze exercises.

While one exercise showed a piece of cheese awaiting the mouse at the end of the maze (the promise of a reward), the other maze depicted a menacing owl nearby (motivation to flee).

Once the participants had traced their way through the mazes with pencils, they were asked to rate the novelty of 33 pictures — nine drawings of space aliens and 24 unrelated images. The students who were prepped to feel an adventurous promotion focus by seeking a reward were much better at spotting the new or different details among these images than the students who’d been cued to have a prevention focus by fleeing a threat.

The conclusion: a promotion focus really does create a mental lens through which new ideas are more visible.

Zhou’s team followed this study with three additional studies, including one that surveyed 44 human resource managers from a variety of companies. For this study, independent coders rated the mission statements of each firm, assessing their cultures as “innovative” or “not innovative.” The HR managers then evaluated a set of written practices — three that had been in use for years, and three new ones that relied on recent technology. The managers from the innovative companies were much better at rating the new HR practices for novelty and creativity. To recognize novelty, in other words, both interior and external environments make a difference.

The implications of the research are groundbreaking. The first ever done on this subject, it opens up a completely new research field with profound questions. Can promotion focus be created? How much of this trait is genetic, and how much based on natural temperament, culture, environment and life experience? Should promotion focus be cultivated in education? If so, what would be the impact? After all, there are important uses for prevention focus, such as corporate security and compliance. Meanwhile, how can workplaces be organized to bring out the best in both kinds of focus?

Leaders eager to put Zhou’s findings to use right away, meanwhile, might look to the real-world model of Michael DeBakey. Practice viewing new ideas as adventures, seek workplaces that actively push innovation and, above all, cultivate the view that every coworker, high or low, is a potential source of glittering new ideas.

---

This article originally appeared on Rice Business Wisdom.

Jing Zhou is the Mary Gibbs Jones Professor of Management and Psychology in Organizational Behavior at the Jones Graduate School of Business of Rice University. Zhou, J., Wang, X., Song, J., & Wu, J. (2017). "Is it new? Personal and contextual influences on perceptions of novelty and creativity." Journal of Applied Psychology, 102(2): 180-202.

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”